| Literature DB >> 30953460 |
Sarah E Neil-Sztramko1, Mary E Medysky2, Kristin L Campbell3, Kelcey A Bland4, Kerri M Winters-Stone2,5.
Abstract
BACKGROUND: The purpose of this review is to update previously published reviews on exercise programming in exercise trials in prostate cancer survivors. We evaluated: 1) the application of the principles of exercise training in prescribed programs; 2) the reporting of the components of the exercise prescription; and 3) the reporting of adherence of participants to the prescribed programs.Entities:
Keywords: Exercise; Exercise prescription; Prostate cancer; Systematic review
Mesh:
Year: 2019 PMID: 30953460 PMCID: PMC6451299 DOI: 10.1186/s12885-019-5520-9
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Exercise training principles
| Principle | Criteria for this review | Example |
|---|---|---|
| Appropriate population targeted and modality selected based on primary outcome | Aerobic exercise such as brisk walking is more appropriate for an intervention aimed at increasing cardiovascular fitness than strength training | |
| Stated exercise programme was progressive and outlined training progression | Increase duration of walking program by 5% every two weeks depending on exercise tolerance | |
| Rationale provided that programme was of sufficient intensity/exercise prescribed relative to baseline capacity | Prescribing intensity in a resistance training program based on % of measured and/or estimated 1-repetition maximum | |
| Selected population with low level of primary outcome measure and/or baseline physical activity levels | Selecting a sample with high baseline fatigue levels to participate in an aerobic training program to increase cardiovascular fitness and reduce fatigue | |
| Performed follow-up assessment on participants who decreased or stopped exercise training after conclusion of intervention | Participants who maintained training after a supervised exercise program preserved strength whereas those who stopped exercising returned to baseline | |
| Performed follow-up assessment of primary outcomes on participants who continued to exercise after conclusion of intervention | Gains in muscle strength are greatest in the first half of a training program unless the training stimulus continually increases |
Fig. 1PRISMA diagram of study selection
Description of included studies
| Authors, Year | Timing | Treatment | N | Intervention | Length (weeks) | Follow-up(weeks) | Primary Outcome* (Tool) | Other Outcomes (Tool) |
|---|---|---|---|---|---|---|---|---|
| Aerobic Exercise Only | ||||||||
| Eriksen et al, 2017 [ | During | AS | 26 | Home | 26 | 12, 37, 52 | NR | VO2 peak (max cycle), lipids, insulin, glucose, PSA, FFM, FM, BMI, WC |
| Hvid et al, 2016 [ | Mixed | AS or RP | 25 | Home | 104 | 12, 24, 36, 52, 78 | NR | VO2 peak (max cycle), BC (DXA), HOMA-IR (OGTT), TC, LDL, HDL, TG, TNF-α, IL-6, adiponectin, leptin, IGF-1, IGFBP-1, glucose, PSA |
| Jones et al, 2014 [ | Mixed | RP | 50 | Sup + Home | 26 | 12, 52 | Erectile Function (IIEF) | VO2 peak (max TM), peripheral artery FMD, glucose, TC, TG, BC (BodPod) |
| Monga et al, 2007 [ | During | RT | 21 | Sup | 8 | – | Fatigue (PFS) | VO2 peak (submax TM), strength (sit-stand) |
| Pernar et al, 2017 [ | After | Mixed | 41 | Sup + Home | 11 | – | NR | BW, WC, BP, CRP, C-peptide, HDL, LDL, testosterone, SHBG |
| Uth et al, 2014 [ | During | ADT | 57 | Sup | 12 | 32 | LBM (DXA) | BMD, BMC, FM (DXA), BW, BMI, WC, HC, WHR, VO2 peak (submax TM), sit-stand, counter-movement jump, stair climb, strength (1RM, knee ext), bone markers |
| Windsor et al, 2004 [ | During | RT | 66 | Home | 4 | – | Fatigue (BFI), Aer fitness (Shuttle walk) | NR |
| Resistance Exercise Only | ||||||||
| Nilsen et al, 2015 [ | During | ADT | 58 | Sup + Home | 16 | – | NR | LBM, BMD, FM, %BF, BW, BMI (DXA), 1RM (knee ext., leg, chest, shoulder press), sit-stand, stair climb, aer fitness (shuttle walk); muscle cell markers, fiber |
| Norris et al, 2015 [ | Mixed | Mixed | 30 | Sup (High) | 12 | – | Strength (est 1RM, bench press, leg press) | Physical function (6MWT, 8 ft. TUG, 30s chair stands, 30s arm curls, S&R, back scratch); BW, BMI, |
| Sup (Low) | ||||||||
| Segal et al, 2003 [ | During | ADT | 155 | Sup | 12 | – | Fatigue (FACT-F) | Muscle endurance (Standard Load), BW, BMI, WC (SkF) |
| Winters-Stone et al, 2014 [ | During | ADT | 51 | Sup + Home | 52 | – | BMD (DXA) | Bone turnover, LM, FM (DXA), insulin, IGF-1, SHBG, testosterone, strength (1RM, leg and chest press), physical function (5 chair stand time, 4 m walk speed) |
| Winters-Stone et al, 2016 [ | After | RT ± CT | 64 | Sup | 24 | 12 | Function (SPPB), MM, FM, %BF (DXA), fatigue (PFS), QoL (SF-36), strength (1RM leg, bench press) | NR |
| Aerobic + Resistance Exercise | ||||||||
| Bourke et al, 2011 [ | During | ADT | 100 | Sup + Home | 12 | 6, 24 | QoL (FACT-P), DBP | VO2 peak (submax TM), strength (Iso-dyn, subgroup), BMI, IGF-1, IGFBP-1, IGFBP-3, insulin, PSA, androgen, testosterone, SHBG; Subgroup: Brachial artery FMD, GTN-mediated brachial artery dilation |
| Cormie et al, 2015 [ | During | ADT | 63 | Sup | 12 | – | LM, FM (DXA) | BMD (DXA), aer fitness (400 m walk), strength (1RM leg press, chest press, seated row), chair stand, stair climb, BP, CRP, TC, TG, insulin, glucose, HbA1C, bone turnover, vitamin D, testosterone, PSA |
| Culos-Reed et al, 2010 [ | During | ADT | 100 | Sup + Home | 16 | 8, 26 | SR-PA (Godin) | Aer fitness (6MWT), strength (Iso-dyn), S&R, BP, HR |
| Galvao et al, 2010 [ | During | ADT | 57 | Sup | 12 | – | LBM, FM, %BF (DXA) | Strength (1RM), Endurance (Time at 70% 1RM), physical function (sit-stand, 6 & 400 m walk), testosterone, PSA, insulin, glucose, lipids, CRP |
| Galvao et al, 2014 [ | After | ADT + RT | 100 | Sup + Home | 52 | 26 | Aer fitness (400 m walk) | Physical function (chair stands), WC, testosterone, PSA, insulin, TC, TG, LDL, HDL, HbA1C, glucose, BP |
| Gaskin et al, 2017 [ | After | Mixed | 320 | Sup + Home | 12 | 26, 52 | SR-PA (LTEQ) | RHR, BP, aer fitness (6MWT), strength (1RM), physical function (30s sit-stand), BW, BMI, WC, HC, upper arm, chest, thigh circumference |
| Hojan et al, 2016 [ | During | RT + ADT | 55 | Sup | 8 | – | NR | PSA, Hb, WBC, RBC, neutrophil, lymphocytes, platelets, monocytes, IL-B, IL-6, TNF-α, Aer fitness (6MWT) |
| Hojan et al, 2017 [ | During | RT + ADT | 72 | Sup | 52 | 8 | Aer fitness (6MWT), IL-1B, IL-6, TNF-a, BMI, WHR, WC, TC, HDL, LDL, TG, AST, ALT | NR |
| Kim, 2018 [ | During | ADT | 51 | Home | 24 | – | BMD (DXA), Bone turnover markers (bs-ALP, NTx) | Strength (grip, hip, HHD), 30s chair-stand, TUG |
| Sajid et al, 2016 [ | During | ADT | 19 | Home | 6 | 12 | Function (SPPB) | Aer fitness (6MWT), strength (grip, chest press reps), FM, LM, MM (DXA) |
| Technology | ||||||||
| Aerobic or Resistance Exercise (Multi-Arm Trials) | ||||||||
| Santa Mina et al, 2013 [ | During | ADT | 26 | Sup + Home Aer | 24 | 12, 52 | QoL (FACT-P, Patient-Oriented Prostate Utility Scale), Fatigue (FACT-F) | VO2 peak (Submax TM), grip strength, BW, BMI, %BF, WC, IGF-1, IGFBP-3, leptin, adiponectin |
| Sup + Home Res | ||||||||
| Segal et al, 2009 [ | During | RT | 121 | Sup Aer | 24 | – | Fatigue (FACT-F) | VO2 peak (max TM), strength (8RM), BW, BC (DXA), testosterone, PSA, Hb, lipids |
| Sup Res | ||||||||
| Wall et al, 2017 [ | During | ADT | 163 | Sup + Home Aer + Res | 52 (26) | – | BMD (DXA), LM, FM, Trunk fat, % BF, (DXA), VO2 peak (Max TM) | RMR, BP, arterial stiffness, HbA1C, testosterone, insulin, PSA, TG, LDL, HDL, TC, glucose, CRP, bs-ALP, PINP, BW, strength (1-RM), endurance (#reps @ 70% 1RM, chest & leg press), chair stands, stair climb, 6 m backward walk, 400 m walk time |
| Sup + Home Impact + Res | ||||||||
| Home Aer | 26 | – | ||||||
Legend: 6MWT: 6 min walk test; ADT: androgen deprivation therapy; Aer: aerobic; ALT: alanine transaminase; AS: active surveillance; AST: aspartate transaminase; BC: body composition; BFI: brief fatigue inventory; BMC: bone mineral content; BMD: bone mineral density; BMI: body mass index; BP: blood pressure; bs-ALP: bone specific alkaline phosphatase; BW: body weight; CRP: c-reactive protein; CT: chemotherapy; DBP: diastolic blood pressure; DXA: dual energy x-ray absorptiometry; ext: extension; FACT-F: functional assessment of cancer therapy – fatigue; FACT-P: functional assessment of cancer therapy – prostate; FFM: fat free mass; FM: fat mass; FMD: flow mediated dilation; Hb: hemoglobin; HbA1C: glycosylated hemoglobin; HC: hip circumference; HDL: high density lipoprotein; HHD: hand held dynamometry; HOMA-IR: homeostatic assessment of insulin resistance; IGF: insulin-like growth factor; IGFBP: insulin-like growth factor binding protein; IIEF: international index of erectile function; IL: interleukin; Iso-dyn: isometric dynamometry; LBM: lean body mass; LDL: low density lipoprotein; LM: lean mass; LTEQ: leisure time exercise questionnaire; Max: maximum; MM: muscle mass; NR: not reported; NTx: type 1 cross-linked N-telopeptide; OGTT: oral glucose tolerance test; PFS: piper fatigue scale; PINP: Pro collagen Type 1 N-Terminal Propeptide; PSA: prostate specific antigen; QoL: quality of life; RBC: red blood cell; Res: resistance; RHR: resting heart rate; RM: repetition maximum; RMR: resting metabolic rate; RP: radical prostatectomy; Res: resistance training; RT: radiation therapy; S&R: sit and reach; SHBG: sex hormone binding globulin; SkF: skin fold; SPPB: short physical performance battery; SR-PA: self-reported physical activity; submax: submaximal; Sup: supervised; TC: total cholesterol; TG: triglycerides; TM: treadmill; TNF-α: tumour necrosis factor-alpha; TUG: timed up and go; VO2 peak: peak oxygen consumption; WBC: white blood cell; WC: waist circumference; WHR: waist-hip ratio; *Where specifically stated
Application of the principles of exercise training and outcomes
| Authors, Year | Sp | Pr | OV | IV | Rev | DR | Significant results |
|---|---|---|---|---|---|---|---|
| Aerobic Exercise Only | |||||||
| Eriksen et al, 2017 [ | NR | NR | NR | NR | ? | ? | ↑VO2 peak (6mo only) |
| Hvid et al, 2016 [ | ? | + | + | + | ? | ? | 6 mo: ↑VO2 peak, adiponectin, IGFBP-1; ↓FM, trunk mass, gynoid FM, android fat; 24 mo: ↓ FM, trunk mass, gynoid FM, android fat, TG, IGF-1, glucose |
| Jones et al, 2014 [ | + | + | + | + | ? | ? | ↑FMD, VO2 peak |
| Monga et al, 2007 [ | + | ? | + | NR | NR | NR | ↑ VO2 peak, Strength; ↓ Fatigue* |
| Pernar et al, 2017 [ | NR | NR | NR | NR | NR | NR | ↑ HDL |
| Uth et al, 2014 [ | NR | + | NR | + | ? | ? | EoS: ↑LBM*, strength, BMC, P1NP, osteocalcin; 32 w: ↑BMD, counter jump, stair climb |
| Windsor et al, 2004 [ | + | NR | ? | NR | ? | ? | ↑ Aer fitness* |
| Resistance Exercise Only | |||||||
| Nilsen et al, 2015 [ | + | + | + | + | NR | NR | ↑Muscle fiber cross-sectional area, strength (leg ext., leg, chest, shoulder press), sit-stand; LBM (lower & upper)* |
| Norris et al, 2015 (High) [ | + | + | + | + | NR | NR | No between group difference |
| Norris et al, 2015 (Low) [ | + | + | + | + | NR | NR | No between group difference |
| Segal et al, 2003 [ | + | + | + | NR | NR | NR | ↓ Fatigue*; ↑Muscle endurance |
| Winters-Stone et al, 2014 [ | + | + | + | + | NR | ? | ↓ FM, ↑strength |
| Winters-Stone et al, 2016 [ | + | + | + | + | NR | + | ↑Upper body strength* |
| Aerobic and Resistance Exercise | |||||||
| Bourke et al, 2011 [ | + | + | NR | + | ? | ? | ↑QoL (12w only)*; VO2 peak, strength, FMD, skeletal MM, SHBG (subgroup only) |
| Cormie et al, 2015 [ | + | + | NR | + | NR | NR | ↑Appendicular LM*, Aer fit, strength, chair stands; ↓ FM*, % BF*, TC |
| Culos-Reed et al, 2010 [ | + | NR | NR | NR | NR | NR | ↑ SR-PA* |
| Galvao et al, 2010 [ | + | ? | ? | NR | NR | NR | ↑ LBM*, Strength, Endurance, 6 m walk; ↓ CRP |
| Galvao et al, 2014 [ | + | ? | NR | + | NR | + | ↑ Aer fitness*, chair stands, strength (6 & 12 mo); appendicular MM (6 mo only), HDL; ↓ TC (12 mo only) |
| Gaskin et al, 2017 [ | + | ? | NR | NR | ? | ? | ↑ Vigorous SR-PA (12wk & 6 mo only)*; Aer fitness, strength, sit-stand; ↓ HC, RHR (12w only) |
| Hojan et al, 2016 [ | + | NR | NR | + | NR | NR | ↑Aer fitness |
| Hojan et al, 2017 [ | + | ? | NR | + | NR | + | ↓ BW, BMI*, WHR*, PSA, IL-6*, ↑ Aer fitness* |
| Kim et al, 2018 [ | + | + | + | + | NR | NR | ↑ Grip strength (left hand), 30s chair stands |
| Sajid et al, 2016 (Home) [ | ? | NR | NR | NR | NR | NR | ↑ SPPB (vs. control)* |
| Sajid et al, 2016 (Tech) [ | ? | NR | NR | NR | NR | NR | None |
| Aerobic or Resistance Exercise (Multi-Arm Trials) | |||||||
| Santa Mina et al, 2013 (Aer) [ | + | NR | NR | NR | ? | + | ↓ BW, WC, BMI (3 mo only) |
| Santa Mina et al, 2013 (Res) [ | + | NR | NR | NR | ? | + | ↑ IGFBP-3 (6 mo only) |
| Sega et al, 2009 (Aer) [ | + | + | + | NR | NR | NR | ↑ VO2 peak |
| Segal et al, 2009 (Res) [ | + | + | + | NR | NR | NR | ↑ VO2 peak, Strength; No %BF; ↓ TG |
| Wall et al, 2017 | + | + | + | + | NR | + | ↑ Strength (6 mo only); Vs. control only: ↑VO2 peak, LM*; ↓ glucose, FM*, trunk FM*, % BF* |
| Wall et al, 2017 | + | + | + | + | NR | + | ↑ Strength (6, 12 mo) |
| Wall et al, 2017 (Aer) [ | + | + | + | + | NR | + | None |
Legend: Aer: aerobic; BMC: bone mineral content; BMD: bone mineral density; BMI: body mass index; BW: body weight; CRP: c-reactive protein; DR: diminishing returns; ext: extension; FM: fat mass; FMD: flow mediated dilation; HC: hip circumference; HDL: high density lipoprotein; IGF: insulin-like growth factor; IGFBP: insulin-like growth factor binding protein; IL: interleukin; IV: initial values; LBM: lean body mass; LM: lean mass; MM: muscle mass; mo: months; NR: not reported; OV: overload; Pr: progression; PSA: prostate specific antigen; QoL: quality of life; Res: resistance; Rev: reversibility; RHR: resting heart rate; SHBG: sex hormone binding globulin; Sp: specificity; SPPB: short physical performance battery; SR-PA: self-reported physical activity; TC: total cholesterol; TG: triglycerides; VO2 peak: peak oxygen consumption; WC: waist circumference; WHR: waist-hip ratio; * Primary outcome
Fig. 2Number of exercise training principles applied across included trials
Fig. 3a Reporting of exercise prescription in study methods. b Reporting of adherence to exercise prescription in study results